Health News from Medical News Today: Sanofi GetGoal Programme On Lyxumia(R) (lixisenatide), As An Add-On To Basal Insulin, Shows Significant Positive Phase III Results

Health News from Medical News Today Latest Health News and Medical News posted throughout the day, every day. Sanofi GetGoal Programme On Lyxumia(R) (lixisenatide), As An Add-On To Basal Insulin, Shows Significant Positive Phase III Results 2 Jun 2011, 5:00 pm Sanofi announced today that new results from a Phase III study showed that the investigational product Lyxumia® (lixisenatide), when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patients with type 2 diabetes without significantly increasing their risk of hypoglycemia. GetGoal-L is one of nine studies in the GetGoal Phase III clinical programme, and the second trial to investigate the benefits of lixisenatide 20µg once-daily combined with basal insulin... You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed.